Evaluation of phlebitis adverse event occurrence in patients of a Clinical Inpatient Unit*

Avaliação da ocorrência do evento adverso flebite em pacientes de uma Unidade de Internação Clínica

Evaluación del acaecimiento del evento adverso flebitis en pacientes de una Unidad de Hospitalización Clínica

ABSTRACT

Objective: To analyze the causes and reasons associated with the occurrence of phlebitis in an Inpatient Medical Unit in a large and private general hospital. Method: Quantitative, exploratory-descriptive, retrospective and documentary research, carried out by consulting the electronic forms of notification of the occurrence of phlebitis in 2017. Results: A total of 107 phlebitis-related cases were reported, most of them (91.7%) with phlebitis, being male (53.1%), aged 60-69 years old (23.0%) and with a hospital stay of less than four days (30.2%). Most (68.2%) of the notifications were made by nurses, with the occurrence of phlebitis predominating in devices with less than 24h (38.3%); with the classification of phlebitis grade 2 (45.8%); with antibiotics infusion (46.7%); with the location of the bed far from the nursing station (52.3%); and with the presence of a companion (82.2%). The damage classification indicated that 93.5% of the patients suffered mild damage, 4.7% moderate damage and 1.9% did not suffer any damage. Conclusion: Knowing the causes and reasons associated with the occurrence of phlebitis can support decision-making, management and care processes regarding investments in preventive or risk mitigation strategies.

DESCRIPTORS

Inpatients; Catheterization, Peripheral; Phlebitis; Nursing Care; Hospital Units.
INTRODUCTION

At some point during hospitalization, intravenous therapy (IVT) is indicated for approximately 80% of patients. Of these, 20% to 70% will develop phlebitis (AE), adverse event (AE), whose signs and symptoms correspond to edema, local heat, hyperemia, fibrous cord in the vessel path, pain, and there may be the presence of purulent secretion in catheter insertion site.

Phlebitis can be mechanical, chemical, bacterial or post-infusional, being classified into: grade 1, presence of hyperemia at the catheter insertion site with or without local pain; grade 2, pain at the catheter insertion site with hyperemia and/or edema and induration; grade 3, pain at the catheter insertion site with hyperemia, induration and palpable venous cord formation; grade 4, pain at the catheter insertion site with hyperemia, induration and palpable venous cord formation with purulent drainage.

A study carried out in an inpatient medical unit (IMU) identified the presence of phlebitis in 60% of patients and in 55.6% of peripheral venous accesses (PVA), the occurrence of which was associated with increased length of hospital stay for these patients. Another study showed that patients hospitalized in surgical and orthopedic units had a lower risk of presenting phlebitis when compared to those who were in IMU, who had a prolonged hospitalization period, as well as the use of corticosteroids and antimicrobials, factors related to the development of phlebitis.

The book To err is human showed the global impact of patient safety and the number of deaths resulting from failures in healthcare. In 2004, the World Alliance for Patient Safety, recognizing the magnitude of the problem, aimed to identify priorities in the area of patient safety and established measures to reduce the risks and the occurrence of AE. In Brazil, Ordinance No. 529, of April 1st, 2013, from the Ministry of Health, instituted the National Patient Safety Program – PNSP (Programa Nacional de Segurança do Paciente) and its premise is to contribute to quality health care at all levels of health care in the country. Recognizing the harm caused to patients, resulting from health care, at the 72nd World Health Assembly, in 2019, the World Health Organization (WHO) adopted resolution WHA72.6, regarding global action on patient safety and recognized this theme as a global health priority.

Phlebitis is a preventable AE and there are strategies that can be implemented, based on the knowledge of risk factors to prevent and/or minimize their occurrence, contributing to the provision of harm-free care. A cohort study with a total of 171 patients with PVA investigated the association between risk factors and the occurrence of phlebitis during use and after removal of PVA, 51.5% of the patients were men, with catheter permanence up to 72 hours and 58.2% of the medications used were sedatives/analgesics. It was identified the need for knowledge about risk factors for phlebitis, in order to contribute to the planning of care by nurses and the identification of patients who may develop phlebitis.

Health professionals, notably nursing professionals, need to understand the importance of their qualified participation, according to their level of governance and in relation to the adoption of preventive measures for phlebitis AE, aiming at obtaining favorable results for patients/users, family members and themselves, for the organization and for society. However, to guide the choice of prevention strategies, it is necessary to know the causes and consequences of this AE, and with this information it will be possible to continuously improve the care and management processes, and ensure the provision of harm-free health services and with reduction of the risks. Thus, this study aims to analyze the causes and reasons associated with the occurrence of phlebitis in the IMU of a general, large and private hospital.

METHOD

TYPE OF STUDY

This is a quantitative, exploratory-descriptive, retrospective and documentary research.

SCENARIO

The General Hospital, the field of study, is private, located in the city of São Paulo and has a total of 512 hospital beds, 38 of which are for IMU. This study comprised the notifications of the occurrence of phlebitis AE in IMU patients, carried out by health professionals by completing the electronic form available on the Hospital intranet.

SELECTION CRITERIA

All electronic forms related to the notification of the occurrence of phlebitis in the IMU patients were selected from January to December 2017.

DATA COLLECTION

From the structuring of electronic forms for notification of phlebitis in the hospital, an instrument was created to document the following information: author (nurse, technician, anonymous, other) and date of notification; patient care number; date of the performed care; physician’s name; consultation number; patient’s age, gender and bed; period (morning, afternoon, night); degree of phlebitis (grade 1: hyperemia, grade 2: hyperemia + local pain, grade 3: hyperemia + local pain + palpable cord, grade 4: hyperemia + local pain + palpable cord and purulent drainage); name of the drug involved; length of the intravenous device in the patient, damage classification (severe, moderate, mild, none); risk assessment for the development of phlebitis (high, moderate, low, no risk); additional information (such as examples, prescription print, photo of the place). The data contained in the instruments were entered into electronic spreadsheets.

DATA ANALYSIS AND TREATMENT

Continuous and semi-continuous data were initially compared with the Gaussian curve using the K-S (Kolmogorov-Smirnov) distance test, determined as non-parametric and expressed using medians, percentiles and compared using the Kruskal-Wallis test, with Muller-Dunn post-test when comparing three or more groups.
Categorical data were represented by absolute (n) and relative (%) frequencies, and the contingency matrices were analyzed using Pearson's Chi-square test or Fisher's Exact Test, when necessary. Complex matrices were partitioned into simple matrices to better determine causality. It was considered, for the whole study, risk $\alpha \leq 0.05$ of making type I or 1st species error, in addition to risk $\beta \leq 0.20$ of making type II or 2nd species error.

**ETHICAL ASPECTS**

The research was approved by the hospital's Research Ethics Committee, through the consubstantiated number: 2.500.262, on February 19th, 2018, meeting all the specifications of Resolution No. 466, from December 12th, 2012, which approves the guidelines and regulatory standards for research involving human beings.

**RESULTS**

In 2017, 3028 hospitalizations occurred in the IMU, with 107 phlebitis AE associated with 96 patients, most (91.7%) affected by one phlebitis. From the notifications analyzed, it was found, as shown in Table 1, that most (53.1%) patients were male, aged 60-69 years old (23%) and with a stay of less than four days (30.2%).

**Table 1** – Distribution of patients affected by phlebitis in the Inpatient Medical Unit, according to gender, age group and length of hospital stay – São Paulo, SP, Brazil, 2019.

| Variables          | N | %  |
|--------------------|---|----|
| **Gender**         |   |    |
| Female             | 45| 46.9|
| Male               | 51| 53.1|
| **Age group**      |   |    |
| 10-19              | 1 | 1.0 |
| 20-29              | 3 | 3.1 |
| 30-39              | 15| 15.6|
| 40-49              | 15| 15.6|
| 50-59              | 13| 13.5|
| 60-69              | 22| 23.0|
| 70-79              | 13| 13.5|
| 80-89              | 10| 10.4|
| 90-99              | 4 | 4.1 |
| **Length of hospital stay (days)** |   |    |
| < 4 days           | 29| 30.2|
| 5-7 days           | 25| 26.0|
| 8-11 days          | 25| 26.0|
| > 12 days          | 17| 17.8|
| **TOTAL**          | 96| 100.0|

The medical diagnostic hypotheses of the 96 patients were grouped into categories, most of them, 70.8%, were hospitalized for infectious diseases; followed by 16.6% for disorders of the central and peripheral nervous system; 9.4% due to digestive system disorders. Among pre-existing diseases, systemic arterial hypertension – SAH (22.9%), diabetes mellitus – DM (15.6%) and dyslipidemia (12.5%) stood out; 19.8% of patients had more than one pre-existing disease. January (13.1%), June (12.1%), July (10.3%) and October (10.3%) were the months with the highest number of notifications. The afternoon and morning shifts had the highest number of notifications (40.2% and 38.3%), carried out by nurses (68.2%); 29.9% notifications were anonymous; 1.9% were performed by nursing technicians. There was no statistically significant difference in relation to the distribution of the degree of 107 phlebitis and to the variables gender, age group and length of hospital stay of patients.

According to Table 2, most (52.3%) phlebitis AE occurred in patients who used the Jelco® intravenous device, with the device remaining in place for 24 hours (38.3%), with a prevalence of grade 2 phlebitis (45.8%), receiving antibiotics (46.7%), with the beds located far from the nursing station (52.3%) and with the presence of a companion (82.2%).

**Table 2** – Characterization of notified phlebitis as to the type of device, length of device in the same place, degree of phlebitis, category of drug infused – São Paulo, SP, Brazil, 2019.

| Variables                          | N | %  |
|------------------------------------|---|----|
| **Type of device**                 |   |    |
| Jelco®                             | 56| 52.3|
| Intima®                            | 51| 47.7|
| **Length of device in the same place** |   |    |
| 24 h                               | 41| 38.3|
| 48 h                               | 28| 26.1|
| 72 h                               | 18| 16.8|
| 96 h                               | 6 | 5.6 |
| 120 h                              | 6 | 5.6 |
| 144 h                              | 5 | 4.8 |
| 168 h                              | 2 | 1.9 |
| Post-removal                       | 1 | 0.9 |
| **Phlebitis degree**               |   |    |
| Grade 1                            | 32| 29.9|
| Grade 2                            | 49| 45.8|
| Grade 3                            | 24| 22.4|
| Grade 4                            | 2 | 1.9 |
| **Drug category**                  |   |    |
| Analgesic                          | 9 | 8.4 |
| Antihistamine                      | 1 | 0.9 |
| Anti-inflammatory                  | 2 | 1.9 |
| Antianemic                         | 1 | 0.9 |
| Antiemetic                         | 3 | 2.8 |
| Antifungal                         | 3 | 2.8 |
| Antibiotic                         | 50| 46.7|
| Antiviral                          | 7 | 6.5 |
| Crystalloid                        | 1 | 0.9 |
| Diuretic                           | 1 | 0.9 |

continue…
When the variable reporter’s function was compared to the degree of phlebitis, there was a statistically significant relationship \((p = 0.007)\) between phlebitis grade 2 and the notification made by the nurse in relation to a notification made anonymously. Nursing technicians reported only two phlebitis referring to grade 1. Out of the 50 (100.0%) patients who received antibiotics, 42.0% had phlebitis grade 2 and 28% phlebitis grade 3. Among the 10 (100.0%) patients who used immunoglobulin, 50.0% had phlebitis grade 3. As for patients located far from the nursing station, 28 (50.0%) had phlebitis grade 2, followed by grade 3 (17.9%) and grade 4 (3.6%).

In the hospital where the study was carried out, nurses are supposed to classify the risk for the development of phlebitis every 24 hours, as an integral part of the Nursing Care Systematization. Regarding this classification, 47.7% of patients corresponded as low risk, 23.4% as moderate risk, 22.4% as high risk and 6.5% as no risk. There was no statistically significant difference between the risk of developing phlebitis and the variables gender, age group, length of stay for patients, pre-existing diseases and grouping of medical diagnostic hypotheses, month of occurrence, shift (morning, afternoon or night) and professional category of the reporter.

Regarding the damage caused, 93.5% of the patients with phlebitis suffered mild damage, 4.7%, moderate and 1.9% did not suffer any damage. There was no record of the occurrence of severe damage or death. However, there was a statistically significant difference in the mild damage associated with pre-existing diseases mental and behavioral disorders \((p = 0.014)\) and hypothyroidism \((p = 0.042)\), regarding the medical diagnostic hypothesis of sepsis \((p = 0.023)\).

As for the damage caused by phlebitis, there was no statistically significant difference when comparing the variables gender, age group, length of stay of patients, month of occurrence, shift and professional category of the reporter, type of intravenous device, length of stay of the device, class of drug, location of the bed in relation to the nursing station and presence of a companion.

Considering the association between damage classification and pre-existing diseases, sepsis and the severity of the phlebitis, there was a significant difference in the occurrence of grade 2 phlebitis associated with pre-existing diseases SAH \((p = 0.020)\), mental and behavioral disorders \((p = 0.020)\) and neuropathy \((p = 0.005)\). Most (40.0%) of patients with SAH had grade 2 (15 – 68.2%) and grade 3 (6 – 27.3%) phlebitis, in addition, three (75.0%) patients with chronic renal failure and nine (75.0%) with dyslipidemia also had phlebitis grade 2. DM was associated with a greater number of patients with phlebitis grade 2 (53.3%) and grade 3 (26.7%), in addition three patients (60.0%) with a diagnostic hypothesis of sepsis presented grade 3 phlebitis.

### Table 3 – Distribution of the degree of phlebitis reported according to the variables pre-existing diseases and diagnostic hypotheses

| Variables                        | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Pearson’s \(\chi^2\)** |
|----------------------------------|---------|---------|---------|---------|------------------------|
| **Pre-existing diseases**        |         |         |         |         |                        |
| **Systemic Arterial Hypertension** |         |         |         |         |                        |
| No                               | 31      | 36.5%   | 34      | 40.0%   | 18                     | 21.2% | 2                     | 2.4%   | 0.02 |
| Yes                              | 1       | 4.5%    | 15      | 68.2%   | 6                      | 27.3% | 0                     | 0.0%   |      |
| **Mental and behavioral disorders** |         |         |         |         |                        |
| No                               | 31      | 30.7%   | 45      | 44.6%   | 24                     | 23.8% | 1                     | 1.0%   | 0.02 |
| Yes                              | 1       | 16.7%   | 4       | 66.7%   | 0                      | 0.0%  | 1                     | 1.67%  |      |
| **Neuropathy**                   |         |         |         |         |                        |
| No                               | 31      | 30.1%   | 47      | 45.6%   | 24                     | 23.3% | 1                     | 1.0%   | 0.005 |
| Yes                              | 1       | 25.0%   | 2       | 50.0%   | 0                      | 0.0%  | 1                     | 25.0%  |      |
| **Chronic Kidney Failure**       |         |         |         |         |                        |
| No                               | 31      | 30.1%   | 46      | 44.7%   | 24                     | 23.3% | 2                     | 1.9%   | 0.611 |
| Yes                              | 1       | 25.0%   | 3       | 75.0%   | 0                      | 0.0%  | 0                     | 0.0%   |      |
| **Dyslipidemia**                 |         |         |         |         |                        |
| No                               | 31      | 32.6%   | 40      | 42.1%   | 22                     | 23.2% | 2                     | 2.1%   | 0.166 |
| Yes                              | 1       | 8.3%    | 9       | 75.0%   | 2                      | 16.70%| 0                     | 0.0%   |      |
| **Sepsis**                       |         |         |         |         |                        |
| No                               | 31      | 30.4%   | 48      | 47.1%   | 21                     | 20.6% | 2                     | 2.0%   | 0.228 |
| Yes                              | 1       | 20.0%   | 1       | 20.0%   | 3                      | 60.0% | 0                     | 0.0%   |      |

\(N = 107\)

---

...continuation
and infused drugs, only Oxacillin (p = 0.007) – belonging to the antibiotic class – showed a statistically significant difference with mild damage.

In Table 4, there was no statistically significant difference correlating the variables length of catheter stay with the degree of phlebitis, damage classification and risk assessment. The median time of permanence of the device in grade 1 phlebitis was 2.5 days; in grade 2 phlebitis, three days; in grade 3 phlebitis, three days; in grade 4 phlebitis, six days. The median time of stay of the device in patients who presented moderate damage was three days, with a variation between three and four days.

### Table 4 – Distribution of catheter stay time, according to the degree of phlebitis, damage classification and risk assessment variables – São Paulo, SP, Brazil, 2019.

| Variables     | Catheter stay time (in days)* |
|---------------|-------------------------------|
|               | Median | 25% | 75% | Sig.**     |
| Phlebitis degree | Grade 1 | 2.5  | 2.0  | 4.0         |
|               | Grade 2 | 3.0  | 2.0  | 5.0         |
|               | Grade 3 | 3.0  | 2.0  | 3.5         |
|               | Grade 4 | 6.0  | 3.0  | 9.0         |
|               | None    | 2.0  | 1.0  | 3.0         |
|               | Mild    | 3.0  | 2.0  | 4.0         |
| Damage classification | Moderate | 3.0  | 3.0  | 4.0         |
|               | Severe  | -    | -    | -           |
|               | No risk | 2.0  | 1.0  | 3.0         |
| Risk assessment    | Low     | 3.0  | 3.0  | 4.0         |
|               | Moderate | 3.0  | 3.0  | 4.0         |
|               | High    | 3.0  | 3.0  | 4.0         |

*Data expressed as median and percentiles, **Kruskal-Wallis test

### DISCUSSION

Frequently, IMU patients remain hospitalized for a long period, they are generally older adults with high dependence on nursing care, and even need the support of the de-hospitalization team to assist in the recovery and hospital discharge process. There are also patients hospitalized for the treatment of infectious and neurological disorders that remain hospitalized for long periods and the IMU is a reference for psychiatric patients who require days of hospitalization for adequate control of their pathology.

A study carried out in a hospital in the northwest of Sao Paulo showed that patients who had phlebitis remained hospitalized on average 22.3 days, 53.4% of these patients for less than 15 days. In the Federal District, the average hospitalization period for patients with phlebitis was 17.86 days (SD ± 14.37), ranging from two to 93 days.

In this study, most (53.1%) of the patients with phlebitis were men, a result similar to those found in the literature. In a survey conducted at the IMU from a university hospital, 51.5% of the patients with phlebitis were men. The number of men hospitalized with chronic non-communicable diseases and complications resulting from lack of treatment is higher, they report not valuing signs and symptoms presented and only seek hospital treatment after weeks and months without any improvement. In addition, they tend to be more resistant to the guidelines of the health team in relation to self-care.

In Zimbabwe, a study assessed risk factors related to the patient and the PVA for the development of phlebitis, and indicated that the age of the patients ranged from 23-80 years old, with 28.2% of the patients being between 30-39 years old, 26.0% were between 40-49, and 23.9% were over 60 years old. Another study showed that 53.0% of the patients with phlebitis were older than 60 years old, a result close to that found in another study, in which 43.7% of the phlebitis reports were associated with patients aged 60 or over.

Older adult patients have a greater number of pre-existing diseases that are risk factors for the development of phlebitis. This study showed that patients with phlebitis had SAH, DM and dyslipidemia as pre-existing diseases, corroborating findings available in the literature. The same occurred with the diagnostic hypothesis, with infectious disease being the main cause of hospitalization for these patients. In the western Brazilian Amazon, the presence of chronic disease and the diagnostic hypothesis of infection showed a statistically significant relationship for phlebitis in hospitalized patients. Multiple pre-existing diseases were also present in 89.3% of individuals who had phlebitis in Zimbabwe.

With regard to the months of greatest phlebitis report in the IMU, it is noteworthy that during the winter the number of hospitalized patients with respiratory disorders was higher, demanding the use of antibiotics that required the installation and maintenance of PVA, factors that could contribute for the development of phlebitis.
A study carried out in a University Hospital evaluated the incidents related to patient safety, of which 344 were AEs, and phlebitis was the fourth cause of report with 13.8%, whereas nurses were responsible for 70.6% of the notifications(19). The notification of AE contributes to the improvement of care, making it possible to identify the causes and propose improvements to mitigate its occurrence.

As for the period of report of the occurrence of phlebitis, a study showed the prevalence in the morning shift (43.7%), due to the greater number of procedures and health professionals to make them feasible, followed by the afternoon shift (40.7%) (19). A report released by Agência Nacional de Vigilância Sanitária (Anvisa) states that, between January 2014 and December 2018, 59.6% of AE reports were made between 7 am and 7 pm; in São Paulo, this value corresponded to 62.7% of the notifications. In the aforementioned period, 14,428 phlebitis were reported in Brazil (20). In Turkey, a cross-sectional study determined the effect of the time of peripheral venous catheter exchange on the development of phlebitis. Devices inserted for less than 48 hours were 5.8 times more likely to present phlebitis than those which were inserted between 49th and 96th hour, the risk was 2.8 times higher, both compared to those with the 97 to 120 hours of catheter time. The incidence of phlebitis was higher in PVA with 48h or less, followed by those with 49 to 96 hours and 97 to 120 hours (21). In Vale do Paraíba, the average stay of venous catheters in patients who developed phlebitis was 49 hours (12). A study that analyzed the incidence of phlebitis in a IMU found that 36.2% of PVA remained on patients up to 72 hours, and 63.8% of PVA had a remaining time greater than 72 hours (1).

In Turkey, a study with 3283 patients evaluated a total of 5,907 PVA divided into two groups: replacement of PVA, when clinically indicated; and replacement of routine PVA, in both groups, in these cases 7.0% of patients had phlebitis. The study showed that the devices could be replaced, when clinically indicated, avoiding the puncture of up to six million devices, reducing the costs related to labor and use of materials for the procedure (22).

In Paraná, phlebitis grade 2 corresponded to most of the notified phlebitis, followed by grade 3 (23). The Rede Sentinela hospital in the city of Recife showed that 63.2% were classified as grade 1, followed by 27.0% as grade 2 and 5.3% as grade 3 (24). In Vale do Paraíba, 41.6% of reports were related to phlebitis grade 1; 37.5% to grade 2; 16.7% at grade 3; and only 4.2% at grade 4 (12). A study carried out in Portugal indicated that phlebitis grades 1 (37.0%) and 2 (53.6%) were also the most present (24). Identifying phlebitis in the first degrees prevents the occurrence of permanent and temporary damage to the patient.

Medicines can contribute to the development of phlebitis due to chemical properties, pH and osmolarity (23). Antibiotics are related to the risks for the development of phlebitis (25) and a higher risk of presenting this AE to a more advanced degree (14). Antibiotics and analgesics are drugs that cause phlebitis due to aspects related to dilution and drug interactions, when salinization is not performed at the end of the infusion (23).

The Infusion Nursing Standards of Practice recommends the use of a catheter with an integrated stabilization system, whenever possible, as it reduces the risk of phlebitis (26). The choice of the device is essential, before the puncture of the PVA evaluating patients is necessary, also knowing the properties of the drug that will be infused, as in the case of irritating and vesicant medications.

It is noteworthy that the occurrence of phlebitis increases the care costs associated with the establishment of a new PVA, in addition to the care that this AE requires, increasing the consumption of materials and the time spent by human resources. As an example, a study carried out in the United States of America indicated that the occurrence of 566 phlebitis, in one month, resulted in the need for 396 new punctures, and the estimated cost of the new PVA corresponded to US$ 13,860 dollars (26).

The analyzed reports indicated that most patients were distant from the nursing station. Therefore, the period that the team demands between answering the call and traveling to the patients’ room may worsen the vessel injury, due to the time to pause/interrupt the medication and evaluate the device.

A limiting aspect of this study was that 20.45% of the notifications did not have records on the procedures adopted during phlebitis. It is noteworthy that the correct notification is extremely important for the quantification of the occurrence of phlebitis and the analysis of the causes and contributing factors, aiming at risk assessment and the adoption of measures to improve patient safety (10). In this logic, medical and nursing professionals should record information related to the care provided in a clear, legible, objective and complete way, with date, time, signature and number of their professional record (27-28).

In order to identify phlebitis signs/symptoms early, evaluation and documentation of the degree of phlebitis in nursing practice using an appropriate scale becomes essential and may assist the nurse in making decisions and establishing the care plan (29).

The systematic orientation of patients and family members, as a strategy adopted in the study field hospital, is an important source of information and prevention of AE. In addition, the hospital has a specific protocol for PVA that has reduced patient discomfort due to multiple punctures and reduces the cost related to the use of materials and human resources in unsuccessful puncture attempts.

Finally, it is understood that analyzing the causes and reasons associated with the occurrence of phlebitis AE contributes to the improvement of knowledge on the subject, in addition to providing subsidies for the construction of care protocols and educational interventions along with health professionals, privileging the adoption of preventive measures.

**CONCLUSION**

A total of 107 phlebitis related to 96 patients were reported, most with a record of the occurrence of one phlebitis (91.7%), mostly in male patients (53.1%), aged 60-69...
years old (23.0%) and with the device remaining on the patient for less than four days (30.2%). The nurse was the professional who made most of the notifications (68.2%). Moreover, there was a predominance: of the occurrence of phlebitis in devices with less than 24 hours (38.3%), classification in grade 2 (45.8%), infusion of antibiotics (46.7%), location of the bed far from the nursing station (52.3%) and the presence of a companion (82.2%). The classification of damage caused by phlebitis indicated that 93.5% of the patients suffered mild damage; 4.7% moderate damage; 1.9% suffered no damage. There was no record of patients classified with severe damage or with death outcome.

RESUMO
Objetivo: Analisar as causas e os motivos associados à ocorrência de flebite na Unidade de Internação Clínica de um hospital geral, que é de grande porte e privado. Método: Pesquisa quantitativa, exploratória-descriptiva, retrospectiva e documental, realizada a partir da consulta aos formulários eletrônicos de notificação da ocorrência de flebite referentes ao ano de 2017. Resultados: Foram notificadas 107 flebites relativas a 96 pacientes, a maioria (91,7%) com uma flebite, do sexo masculino (53,1%), na faixa etária de 60-69 anos (23,0%) e com tempo de permanência inferior a quatro dias (30,2%). A maioria (68,2%) das notificações foi realizada por enfermeiros, tendo predominado a ocorrência de flebite nos dispositivos com tempo inferior a 24h (38,3%), a classificação flebite grau 2 (45,8%), a infusão de antibióticos (46,7%), a localização do leito distante do posto de enfermagem (52,3%) e a presença de acompanhante (82,2%). A classificação de danos indicou que 93,5% dos pacientes sofreram danos leves, 4,7%, danos moderados e 1,9% não sofreram danos. Conclusão: Conhecer as causas e os motivos associados à ocorrência de flebite poderá subsidiar os processos decisórios, gerencial e assistencial, quanto aos investimentos em estratégias preventivas ou de mitigação de riscos.

DESCRITORES
Pacientes Internados; Cateterismo Periférico; Flebite; Cuidados de Enfermagem; Unidades Hospitalares.

REFERENCES
1. Zheng GH, Yang L, Chen HY, Chu JF, Mei L. Aloe vera for prevention and treatment of infusion phlebitis. Cochrane Database Syst Rev. 2014;(6):CD009162. https://doi.org/10.1002/14651858.CD009162.pub2
2. Gorski LA. The 2016 Infusion therapy standards of practice. Home Healthc Now. 2017;35(1):10-8. https://doi.org/10.1097/NHH.0000000000000481
3. Abdul-Hak CK, Barros AF. The incidence of phlebitis in a Medical Clinical Unit. Texto Contexto Enferm. 2014;23(3):633-8. https://doi.org/10.1590/0104-07072014000900013
4. Cicolini G, Manzoli L, Simonetti V, Flacco ME, Comparcini D, Capasso L, et al. Phlebitis risk varies by peripheral venous catheter site and increases after 96 hours: a large multi-centre prospective study. J Adv Nurs. 2014;70(11):2539-49. https://doi.org/10.1111/jan.12403
5. Kohn LT, Corrigan JM, Donaldson MC, editors. To err human: building a safer health system. Washington: National Academy Press; 1999.
6. World Health Organization. World alliance for patient safety: forward programme [Internet]. Geneve: World Health Organization; 2004 [cited 2017 Sep 15]. Available from: http://www.who.int/patientsafety/en/brochure_final.pdf
7. Brasil. Ministerio da Saúde. Programa Nacional de Segurança do Paciente [Internet]. Brasília, DF: Ministério da Saúde; 20172004 [cited 2018;12(3):745-52. https://doi.org/10.5205/1981-8963-v12i3a23045p745-752-2018
8. Rev Latino-Am Enferm. 2016;24:e2746. http://dx.doi.org/10.1590/1518-8345.0604.2746
9. World Health Organization. Global action on patient safety [Internet]. 2019 [cited 2020 Feb 4] May 28. Available from: https://apps.who.int/ghwbh/pdf_files/WHA72/A72_R6-en.pdf
10. Urbanetto JS, Peixoto CG, May TA. Incidence of phlebitis associated with the use of peripheral IV catheter and following catheter removal. Rev Latino-Am Enferm. 2016;24:e2746. http://dx.doi.org/10.1590/1518-8345.0604.2746
11. Beccaria LM, Machado BD, Bertolli ES, Contrim LR, Wermnek AL. Incidete of phlebitis in adult patients. Rev Enferm UFPE On Line. 2018;11;3:(5):745-52. https://doi.org/10.5202/ruev1981-8963-v11i3a23045p745-752-2018
12. Tertuliano AC, Borges JLS, Fortunato RAS, Poveda VB, Oliveira AL. [Phlebitis associated with peripheral intravenous catheter among in-patients of a Hospital in Vale do Paraíba]. Rev Min Enferm. 2014;18(2):334-45. Portuguese. https://doi.org/10.5933/1415-2762.20140026
Evaluation of phlebitis adverse event occurrence in patients of a Clinical Inpatient Unit

13. Souza AE, Oliveira JL, Dias DC, Nicola AL. [Prevalence of phlebitis in adult patients admitted to a university hospital]. Rev RENE. 2015;16(1):114-22. Portuguese. https://doi.org/10.15253/2175-6783.201500100015

14. Nyika ML, Tekonha E, Zvinavashe M. Factors contributing to phlebitis among adult patients admitted in the medical-surgical units of a Central Hospital in Harare, Zimbabwe. J Infus Nurs. 2018;41(2):96-103. https://doi.org/10.1097/NAN.0000000000000265

15. Milutinović D, Simin D, Zec D. Risk factor for phlebitis: a questionnaire study of nurses’ perception. Rev Latino-Am Enferm. 2015;23(4):677-84. https://doi.org/10.1590/0104-1169.0192.2603

16. Danski MT, Johann DA, Vayego SA, Oliveira GR, Lind J. Complications related to the use of peripheral venous catheters: a randomized clinical trial. Acta Paul Enferm. 2016;29(1):84-92. https://doi.org/10.1590/1982-0194201600012

17. Braga LM, Parreira PM, Oliveira AS, Mónico LS, Arengu-Sena C, Henriques MA. Phlebitis and infiltration: vascular trauma associated with the peripheral venous catheter. Rev Latino-Am. Enferm. 2018;26:e3002. https://doi.org/10.1590/1518-8345.2377.3002

18. Enes SM, Opitz SP, Faro AR, Pedreira ML. Phlebitis associated with peripheral intravenous catheters in adults admitted to hospital in the Western Brazilian Amazon. Rev Esc Enferm USP. 2016;50(2):263-71. https://doi.org/10.1590/0080-62342016000200012

19. Furtini AC, Nunes AA, Damora ME. Notifications of adverse events: characterization of the events that occurred in a hospital complex. Rev Gaúcha Enferm. 2019;40(esp):e20180317. https://doi.org/10.1590/1983-1447.2019.20180317

20. Brasil. Ministério da Saúde. Agência Nacional de Vigilância Sanitária. Relatório Brasil e Estado de São Paulo - 2018. Brasília, DF: Anvisa; 2018.

21. Pasalioglu KB, Kaya H. Catheter indwell time and phlebitis development during peripheral intravenous catheter administration. Pak J Med Sci. 2014;30(4):725-30. https://doi.org/10.12669/pjms.304.5067

22. Rickard CM, Webster J, Wallis MC, Marsh N, McGrail MR, French V, et al. Routine versus clinically indicated replacement of peripheral intravenous catheters: a randomised controlled equivalence trial. Lancet. 2012;380(9847):1066-74. https://doi.org/10.1016/S0140-6736(12)61082-4

23. Oliveira ECS, Oliveira APB, Oliveira RC. Characterization of phlebitis notifications to risk management in hospital sentinel network. Rev Baiana Enferm. 2016;30(2):1-9. Portuguese https://doi.org/10.1590/1982-0194201600012

24. Salgueiro-Oliveira A, Parreira P, Veiga P. Incidence of phlebitis in patients with peripheral intravenous catheters: the influence of some risk factors. Aust J Adv Nurs [Internet]. 2012 [cited 2019 Mar 16];30(2):32-9. Available from: https://search.informit.com.au/documentSummary;dn=089105424571588;res=ielapa

25. Urbanetto JS, Freitas AP, Oliveira AP, Santos JC, Muniz FO, Silva RM, et al. Risk factors for the development of phlebitis: an integrative review of literature. Rev Gaúcha Enferm. 2018;38(4):e57489. https://doi.org/10.1590/1983-1447.2017.04.57489

26. Jones RK. Short peripheral catheter quality and economics: the intravenous quotient. J Infus Nurs. 2018;41(6):365-71. https://doi.org/10.1097/NAN.0000000000000303

27. Conselho Federal de Medicina. Resolução CFM nº 193/2009. Código de Ética Médica. Capítulo X - Documentos médicos. Diário Oficial União, Brasília, DF. 2009 Sep 17.

28. Conselho Federal de Enfermagem. Resolução COFEN nº 311/2007. Código de Ética dos Profissionais de Enfermagem. Diário Oficial União, Brasília, DF. 2007 Feb 13.

29. Braga LM, Salgueiro ASO, Pereira HMA, Alves RM, Vidal RCJ, Pereira SAG et al. Translation and adaptation of the Phlebitis Scale for the Portuguese population. Rev Enf Ref. 2016;serIV(11):101-9. https://doi.org/10.12707/RIV16048

Financial support

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).

This is an open-access article distributed under the terms of the Creative Commons Attribution License.